Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Janux Therapeutics, Inc.NASDAQ: JANX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $26.81M rose 7.0% year over year, behind the +60.8% change in trailing-twelve-month research & development. Sequentially, it fell 15.0% from the prior quarter. Over 3 fiscal years it compounded at +33.1% a year.
Context
- Research & development amounted to 1259.0% of revenue in FY2025, up 613.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.0% toward the trailing-twelve-month pace of +60.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 125.9M USD
- Year-over-year change
- +84.1%
- 4-year CAGR
- +48.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 125.9M | +84.1% |
| FY2024 | 2024-12-31 | 68.39M | +24.5% |
| FY2023 | 2023-12-31 | 54.92M | +2.8% |
| FY2022 | 2022-12-31 | 53.44M | +103.7% |
| FY2021 | 2021-12-31 | 26.24M | — |
Research & Development vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +60.8% is the highest of 10, against a peer median of +22.3%.
- Research & development amounts to 590.6% of revenue for JANX, versus a peer median of 173.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $378.58M USD | -9.4% | +7.3% | 27.9% | |
| LTM Sep 2026 | $283.32M USD | +31.2% | +43.9% | 252960.7% | |
| LTM Sep 2026 | $236.54M USD | +35.6% | +95.7% | — | |
| LTM Mar 2026 | €201.11M EUR | +27.4% | +19.9% | 539.2% | |
| LTM Mar 2026 | $188.07M USD | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $151.37M USD | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $127.65M USD | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $69.1M USD | -13.8% | -14.9% | 194.4% | |
| LTM Mar 2026 | $56.29M USD | +22.7% | +23.1% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | +22.3% | +19.9% | 173.2% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Cost of Revenue | 26.24M | 841K | 1.96M | 2.06M | 2.03M |
| Gross Profit | (22.6M) | 7.77M | 6.13M | 8.53M | 7.97M |
| Gross Margin | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| Research & Development | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| Selling, General & Admin | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Operating Expenses | 10.33M | 74.86M | 79.11M | 107.38M | 165.64M |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| EBITDA | (32.56M) | (62.22M) | (56.34M) | (66.93M) | (111.6M) |
| EBITDA Margin | -895.2% | -722.5% | -697.0% | -632.2% | -1116.0% |
| Operating Income | (32.93M) | (67.09M) | (72.98M) | (98.85M) | (157.67M) |
| Operating Margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Interest Income | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Income Before Tax | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Pre-Tax Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Net Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (Basic) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| EPS (Diluted) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| Weighted Avg Shares | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Weighted Avg Shares (Diluted) | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.